Qrxpharma (QRX)

Shares / Stock Code


Stock Exchange / Sharemarket

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain management and central nervous system (CNS) disorders. Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, QRxPharma’s product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales. The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets. Company listed on Australian Stockmarket (ASX) on 25 May, 2007. QRxPharma’s lead compound, MoxDuo™IR (Q8003IR), is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. Study results consistently demonstrate MoxDuo™IR’s greater overall tolerability, achieving as good or better pain relief with substantially fewer incidences of moderate to severe side effects. The Company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. During the year ended June 30, 2009, it completed 197 patient Phase 3 program comparative studies at six United States clinical research sites. A second Phase 3 program pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo IR capsules in 44 patients who underwent knee replacement surgery against Percocet was also initiated. MoxDuo IV clinical trial activity was initiated to evaluate formulation of QRxPharma’s Dual Opioid, MoxDuo IV for postsurgical treatment of hospital-based pain.

Qrxpharma (QRX) Products and Services

  • The Company is a clinical stage specialty pharmaceutical company focused on developing and commercialising therapies to treat disorders of the central nervous system.

Qrxpharma (QRX) Locations and Subsidiaries

Qrxpharma Head Office Level 1, 194 Miller Street, NORTH SYDNEY, NSW, AUSTRALIA, 2060 Phone: (02) 9492 8021 Fax: (02) 8920 0314

Qrxpharma (QRX) Share Price

Submitted by ASX Listed Company on 22 May, 2010 - 17:07